Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis

Fang Wang, Jing Li, Anthony L. Sinn, W. Eric Knabe, May Khanna, Inha Jo, Jayne M. Silver, Kyungsoo Oh, Liwei Li, George Sandusky, George W. Sledge, Harikrishna Nakshatri, David R. Jones, Karen Pollok, Samy Meroueh

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Virtual screening targeting the urokinase receptor (uPAR) led to (±)-3-(benzo[d][1,3]dioxol-5-yl)-N-(benzo[d][1,3]dioxol-5-ylmethyl) -4-phenylbutan-1-amine 1 (IPR-1) and N-(3,5-dimethylphenyl)-1-(4- isopropylphenyl)-5-(piperidin-4-yl)-1H-pyrazole-4-carboxamide 3 (IPR-69). Synthesis of an analogue of 1, namely, 2 (IPR-9), and 3 led to breast MDA-MB-231 invasion, migration and adhesion assays with IC 50 near 30 μM. Both compounds blocked angiogenesis with IC 50 of 3 μM. Compounds 2 and 3 inhibited cell growth with IC 50 of 6 and 18 μM and induced apoptosis. Biochemical assays revealed leadlike properties for 3, but not 2. Compound 3 administered orally reached peak concentration of nearly 40 μM with a half-life of about 2 h. In NOD-SCID mice inoculated with breast TMD-231 cells in their mammary fat pads, compound 3 showed a 20% reduction in tumor volumes and less extensive metastasis was observed for the treated mice. The suitable pharmacokinetic properties of 3 and the encouraging preliminary results in metastasis make it an ideal starting point for next generation compounds.

Original languageEnglish
Pages (from-to)7193-7205
Number of pages13
JournalJournal of Medicinal Chemistry
Volume54
Issue number20
DOIs
StatePublished - Oct 27 2011

Fingerprint

Urokinase-Type Plasminogen Activator
Breast
Pharmacokinetics
Breast Neoplasms
Neoplasm Metastasis
Inbred NOD Mouse
SCID Mice
Tumor Burden
Amines
Half-Life
Adipose Tissue
Apoptosis
Growth

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. / Wang, Fang; Li, Jing; Sinn, Anthony L.; Knabe, W. Eric; Khanna, May; Jo, Inha; Silver, Jayne M.; Oh, Kyungsoo; Li, Liwei; Sandusky, George; Sledge, George W.; Nakshatri, Harikrishna; Jones, David R.; Pollok, Karen; Meroueh, Samy.

In: Journal of Medicinal Chemistry, Vol. 54, No. 20, 27.10.2011, p. 7193-7205.

Research output: Contribution to journalArticle

Wang, Fang ; Li, Jing ; Sinn, Anthony L. ; Knabe, W. Eric ; Khanna, May ; Jo, Inha ; Silver, Jayne M. ; Oh, Kyungsoo ; Li, Liwei ; Sandusky, George ; Sledge, George W. ; Nakshatri, Harikrishna ; Jones, David R. ; Pollok, Karen ; Meroueh, Samy. / Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. In: Journal of Medicinal Chemistry. 2011 ; Vol. 54, No. 20. pp. 7193-7205.
@article{d64e83e9a5434267924b0a744d86406a,
title = "Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis",
abstract = "Virtual screening targeting the urokinase receptor (uPAR) led to (±)-3-(benzo[d][1,3]dioxol-5-yl)-N-(benzo[d][1,3]dioxol-5-ylmethyl) -4-phenylbutan-1-amine 1 (IPR-1) and N-(3,5-dimethylphenyl)-1-(4- isopropylphenyl)-5-(piperidin-4-yl)-1H-pyrazole-4-carboxamide 3 (IPR-69). Synthesis of an analogue of 1, namely, 2 (IPR-9), and 3 led to breast MDA-MB-231 invasion, migration and adhesion assays with IC 50 near 30 μM. Both compounds blocked angiogenesis with IC 50 of 3 μM. Compounds 2 and 3 inhibited cell growth with IC 50 of 6 and 18 μM and induced apoptosis. Biochemical assays revealed leadlike properties for 3, but not 2. Compound 3 administered orally reached peak concentration of nearly 40 μM with a half-life of about 2 h. In NOD-SCID mice inoculated with breast TMD-231 cells in their mammary fat pads, compound 3 showed a 20{\%} reduction in tumor volumes and less extensive metastasis was observed for the treated mice. The suitable pharmacokinetic properties of 3 and the encouraging preliminary results in metastasis make it an ideal starting point for next generation compounds.",
author = "Fang Wang and Jing Li and Sinn, {Anthony L.} and Knabe, {W. Eric} and May Khanna and Inha Jo and Silver, {Jayne M.} and Kyungsoo Oh and Liwei Li and George Sandusky and Sledge, {George W.} and Harikrishna Nakshatri and Jones, {David R.} and Karen Pollok and Samy Meroueh",
year = "2011",
month = "10",
day = "27",
doi = "10.1021/jm200782y",
language = "English",
volume = "54",
pages = "7193--7205",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "20",

}

TY - JOUR

T1 - Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis

AU - Wang, Fang

AU - Li, Jing

AU - Sinn, Anthony L.

AU - Knabe, W. Eric

AU - Khanna, May

AU - Jo, Inha

AU - Silver, Jayne M.

AU - Oh, Kyungsoo

AU - Li, Liwei

AU - Sandusky, George

AU - Sledge, George W.

AU - Nakshatri, Harikrishna

AU - Jones, David R.

AU - Pollok, Karen

AU - Meroueh, Samy

PY - 2011/10/27

Y1 - 2011/10/27

N2 - Virtual screening targeting the urokinase receptor (uPAR) led to (±)-3-(benzo[d][1,3]dioxol-5-yl)-N-(benzo[d][1,3]dioxol-5-ylmethyl) -4-phenylbutan-1-amine 1 (IPR-1) and N-(3,5-dimethylphenyl)-1-(4- isopropylphenyl)-5-(piperidin-4-yl)-1H-pyrazole-4-carboxamide 3 (IPR-69). Synthesis of an analogue of 1, namely, 2 (IPR-9), and 3 led to breast MDA-MB-231 invasion, migration and adhesion assays with IC 50 near 30 μM. Both compounds blocked angiogenesis with IC 50 of 3 μM. Compounds 2 and 3 inhibited cell growth with IC 50 of 6 and 18 μM and induced apoptosis. Biochemical assays revealed leadlike properties for 3, but not 2. Compound 3 administered orally reached peak concentration of nearly 40 μM with a half-life of about 2 h. In NOD-SCID mice inoculated with breast TMD-231 cells in their mammary fat pads, compound 3 showed a 20% reduction in tumor volumes and less extensive metastasis was observed for the treated mice. The suitable pharmacokinetic properties of 3 and the encouraging preliminary results in metastasis make it an ideal starting point for next generation compounds.

AB - Virtual screening targeting the urokinase receptor (uPAR) led to (±)-3-(benzo[d][1,3]dioxol-5-yl)-N-(benzo[d][1,3]dioxol-5-ylmethyl) -4-phenylbutan-1-amine 1 (IPR-1) and N-(3,5-dimethylphenyl)-1-(4- isopropylphenyl)-5-(piperidin-4-yl)-1H-pyrazole-4-carboxamide 3 (IPR-69). Synthesis of an analogue of 1, namely, 2 (IPR-9), and 3 led to breast MDA-MB-231 invasion, migration and adhesion assays with IC 50 near 30 μM. Both compounds blocked angiogenesis with IC 50 of 3 μM. Compounds 2 and 3 inhibited cell growth with IC 50 of 6 and 18 μM and induced apoptosis. Biochemical assays revealed leadlike properties for 3, but not 2. Compound 3 administered orally reached peak concentration of nearly 40 μM with a half-life of about 2 h. In NOD-SCID mice inoculated with breast TMD-231 cells in their mammary fat pads, compound 3 showed a 20% reduction in tumor volumes and less extensive metastasis was observed for the treated mice. The suitable pharmacokinetic properties of 3 and the encouraging preliminary results in metastasis make it an ideal starting point for next generation compounds.

UR - http://www.scopus.com/inward/record.url?scp=80054883036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054883036&partnerID=8YFLogxK

U2 - 10.1021/jm200782y

DO - 10.1021/jm200782y

M3 - Article

VL - 54

SP - 7193

EP - 7205

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 20

ER -